Warfarin Pharmacogenomics Model
Model Introduction and Explanation
This warfarin pharmacogenomics risk-benefit analysis model is intended to serve as a tool for stakeholders to evaluate the potential impact of genotype-guided warfarin dosing versus standard of care dosing in terms of clinical events (i.e. major bleeding events, major clotting events, and deaths). The model is structured in a manner that allows the user to specify the average amount of time patients spend above, within, and below the targeted International Normalized Ratio (INR) range, the number of patients under evaluation, and the duration of evaluation (ranging from 1 to 3 months). Based on these inputs, and results from prior randomized and observational warfarin studies, the model calculates the estimated number of clinical events in the given population over the given period of time.
Download the warfarin pharmacogenomics risk-benefit analysis model in Excel spreadsheet form.
*Click the hyperlink above to download the warfarin pharmacogenomics risk-benefit analysis model. This action should save the model to the default location on your hard drive for internet downloads (e.g. desktop or documents folder). Once the model is saved on your hard drive, you can open the excel file, change model inputs, and save changes to the model.
**The warfarin pharmacogenomics risk-benefit model utilizes Microsoft excel macros to reset values on the main user page. Users must choose to enable macros when they open the excel file in order to have this functionality. Most of the model functions will work for users who do not want to enable macros, or are using versions of excel that do not allow macros, however the model will not reset the values on the main user page in this case.